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Abstract
Background: Cardiac cell death and generation of oxidative stress contribute to doxorubicin (DOX)-induced cardiac
dysfunction. E3 ligase Nrdp1 plays a critical role in the regulation of cell apoptosis, inflammation and production of reactive
oxygen species (ROS), which may contribute to heart failure. However, the role of Nrdp1 in DOX-induced cardiac injury
remains to be determined.
Methods and Results: We examined the effect of Nrdp1 overexpression with DOX treatment in rat neonatal cardiomyocytes
and mouse heart tissue. Cardiomyocytes were infected with adenovirus containing GFP (Ad-GFP), Nrdp1 wild-type (Ad-
Nrdp1) or the dominant-negative form of Nrdp1 (Ad-Dn-Nrdp1), then treated with DOX for 24 hr. DOX treatment increased
cell death and apoptosis, with Ad-Nrdp1 infection enhancing these actions but Ad-Dn-Nrdp1 infection attenuating these
effects. Furthermore, 5 days after a single injection of DOX (20 mg/kg, intraperitoneally), Nrdp1 transgenic mice (TG) showed
decreased cardiac function and increased apoptosis, autophagy and oxidative stress as compared with wild-type (WT) mice
(P,0.01). Survival rate was significantly lower in Nrdp1 TG mice than in WT mice 10 days after DOX injection (P,0.01).
Conclusions/Significance: These results were associated with decreased activation of Akt, extracellular signal-regulated
kinase 1/2 (ERK1/2) and signal transducer and activator of transcription 3 (STAT3) signaling pathways. Nrdp1 may be a key
mediator in the development of cardiac dysfunction after DOX treatment and associated with inhibition of Akt, ERK1/2 and
STAT3. Nrdp1 may be a new therapeutic target in protecting against the cardiotoxic effects of DOX.
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Introduction
Doxorubicin (DOX), an anthracycline antibiotic, is one of the
most potent anti-neoplastic agents used to treat various solid and
hematogenic tumors [1]. Cardiotoxicity leading to congestive
heart failure is the major factor limiting the clinical use of DOX
[1,2]. Despite intensive investigations of DOX-induced cardiotox-
icity, the molecular mechanisms underlying DOX-induced cardiac
injury and dysfunction have not been completely elucidated.
Emerging evidence from animal and human studies indicates that
DOX-induced cardiomyopathy is mainly caused by increased
production of reactive oxygen species (ROS), inflammation,
apoptotic cell death and vacuolization of myocardial cells, which
are the typical changes in DOX-induced heart failure [3,4].
Nrdp1 (also known as FLRF or RBCC) is a newly defined RING
finger E3 ubiquitin ligase that has important roles in regulating cell
growth, apoptosis, and oxidative stress in various cell types [5,6,
7,8,9,10]. Accumulating evidence indicates that Nrdp1 promotes
ubiquitination and degradation of the epidermal growth-factor
receptor family member ErbB3, the gigantic (530 kDa) inhibitor-
of-apoptosis protein BRUCE, and Parkin, which have been
implicated in the pathology of numerous disorders, including heart
valve formation, cancer, Parkinson’s disease, and endotoxin shock
[5,6,7,8,9,10,11]. Recently, we demonstrated that cardiac-specific
overexpression of Nrdp1 can promote cardiac myocyte apoptosis
induced by ischemia-reperfusion (I/R) injury in transgenic mice,
and inhibition of endogenous Nrdp1 in cardiomyocytes protects
against I/R-triggered apoptosis in vitro [12]. However, the
functions of Nrdp1 in DOX-induced cardiomyopathy and its
underlying mechanism(s) have not been investigated.
On the basis of our prior findings, we postulated that increased
Nrdp1 levels would exacerbate DOX-triggered cardiotoxicity. We
investigated the role of Nrdp1 in DOX-induced cardiomyocyte
death and production of oxidative stress, as well as mouse survival
and left ventricle (LV) function. We studied the activation of Akt,
extracellular signal-regulated kinase 1/2 (ERK1/2), and signal
transducer and activator of transcription 3 (STAT3) pathways in
the process.
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Effect of DOX on the expression of Nrdp1 in rat neonatal
cardiomyocytes and mouse heart
To investigate the role of Nrdp1 in cardiac injury in response to
DOX treatment, we first examined the expression of endogenous
Nrdp1 in mouse heart tissues at different times; Nrdp1 protein level
was time-dependently upregulated with intraperitoneal (ip)
injection of 20 mg/kg DOX (Figure 1A). This result was further
confirmed in rat neonatal cardiomyocytes after 0.5 mM DOX
treatment (Figure 1B). DOX treatment simulating Nrdp1 expres-
sion in cardiomyocytes suggested that Nrdp1 might be involved in
DOX-induced cardiotoxicity.
DOX-induced cardiomyocyte death is suppressed by
dominant-negative Nrdp1
To determine whether Nrdp1 could affect DOX-induced
cardiomyocyte death, rat neonatal cardiomyocytes were infected
with Ad-GFP, Ad-Nrdp1 or Ad-Dn-Nrdp1 (lacking E3 ubiquitin
ligase activity). The infection efficiency was .95% after 24 hr
(Figure 2A). Infected cells were subsequently subjected to DOX
(0.5 mM) or saline treatment. Cell viability, TUNEL-positive cells
and level of cleaved poly ADP-ribose polymerase (PARP), an
indicator of programmed cell death were similar among the
groups after saline treatment (Figure 2B–D). At 24 hr after DOX
treatment, cell viability was markedly decreased, and TUNEL-
positive cells and cleaved PARP level were significantly increased
in Ad-GFP-infected groups as compared with saline-treated
groups. These effects were further enhanced with Ad-Nrdp1
infection. In contrast, these alterations were markedly diminished
with Ad-Dn-Nrdp1 infection, which suggests that Nrdp1 can
promote DOX-induced cell death and apoptosis.
Nrdp1 overexpression enhances DOX-induced cardiac
injury and apoptosis
To confirm whether Nrdp1 overexpression affects DOX-induced
cardiac injury and apoptosis in vivo, we created transgenic mice
(TG) overexpressing Nrdp1 under the control of the cardiac-
specific a-myosin heavy chain (a-MHC) promoter. Nrdp1 TG
hearts showed a 2.8-fold increase in total (transgenic and
endogenous) Nrdp1 content as compared with WT hearts [12].
At 5 days after DOX injection, WT hearts showed focal
cytoplasmic vacuolization, a hallmark of cell injury, which is
consistent with previous reports [13,14], and this alteration was
greater in TG than WT hearts (Figure 3A). Electron microscopy
further demonstrated severe vacuolar degeneration in DOX-
treated Nrdp1 TG hearts as compared with WT hearts (Figure 3B).
Furthermore, the proportion of TUNEL-positive nuclei was 2.1-
fold higher in DOX-treated TG than WT hearts (Figure 3C).
Accordingly, the protein levels of cleaved PARP and p53 were
markedly higher in DOX-treated WT than saline-treated WT
mice, and the increased expression of these proteins was induced
by 45% in DOX-treated TG hearts as compared with controls
(Figure 3D). Thus, overexpression of Nrdp1 in vivo significantly
increased DOX-induced cardiac injury and apoptosis.
Effect of Nrdp1 on DOX-induced autophagy
A recent study demonstrated that DOX induces autophagy in
cardiomyocytes, and increased autophagy promotes DOX-
induced cardiomyocyte death [15]. We thus examined whether
overexpression of Nrdp1 could affect DOX-induced autophagy in
the mouse heart. Microtubule-associated protein light 1 chain 3
(LC3), a mammalian homologue of yeast Atg8, is processed from
LC3-I (18 kDa) to -II (16 kDa) and incorporated into autophagic
vacuoles, and the quantification of the ratio of LC3-II to -I is a
good marker of autophagy induction [16]. Western blot analysis
showed that the baseline ratio of LC3-II to -I was similar in WT
and Nrdp1 TG hearts. After 24 hr of DOX injection, the ratio was
significantly higher in DOX-treated than saline-treated WT hearts
and was greater after DOX treatment in TG than WT hearts
(Figure 4A). Consistent with the immunoblotting results of LC3
expression, electron microscopy after DOX treatment revealed a
marked accumulation of vacuoles in WT cardiomyocytes, which
was exaggerated in TG cardiomyocytes, most of which were
electron-dense lysosomes (Figure 4B). The ultrastructure of
cardiomyocytes was not affected by saline treatment (Figure 4B).
Thus, overexpression of Nrdp1 in vivo could increase DOX-induced
autophagy in the mouse heart.
Figure 1. DOX stimulates Nrdp1 protein expression. Time-course of the protein expression of Nrdp1 in mouse hearts (n=3) after
intraperitoneal (ip) injection of 20 mg/kg DOX (A) or in neonatal rat cardiomyocytes after 0.5 mM DOX treatment (B). b-actin was used as a loading
control. Quantitative analysis is in bottom panels (n=3 experiments for each time points). *P,0.05 vs 0 hour.
doi:10.1371/journal.pone.0021104.g001
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Previous study showed that Nrdp1 plays an important role in
ROS generation in SH-SY5Y cells [7]. We thus compared the
levels of 2 oxidative stress markers, malondialdehyde (MDA) and
glutathione peroxidase (GPX) in heart tissues from WT and Nrdp1
TG mice. MDA level and GPX activity did not differ between WT
and TG hearts after saline injection (Figure 5A and B). After 4
days of DOX administration, MDA level was increased and GPX
activity decreased in WT and TG hearts as compared with saline-
treated hearts (P,0.05). Moreover, these changes in MDA level
and GPX activity were greater in TG than WT hearts (P,0.05).
Cardiac-specific expression of Nrdp1 promotes DOX-
induced cardiac dysfunction
Given the marked disparity of cardiomyocyte injury and cell
death between WT and Nrdp1 TG mice after DOX administra-
tion, we assessed cardiac contractile function by in vivo echocar-
diography. Figure 6A shows representative echocardiograms after
saline or DOX administration in WT and TG mice. Systolic,
diastolic, and cardiac function did not differ between WT and TG
mice after saline injection. However, at 4 days after DOX
injection (20 mg/kg), LVEDD and LVESD were greater in WT
alone than saline-treated WT hearts, and the increased LVEDD
Figure 2. Effects of Nrdp1 on DOX-induced cell death in rat neonatal cardiomyocytes. A. The infection efficiency of cardiomyocytes with
Ad-GFP, Ad-Nrdp1 and Ad-Dn-Nrdp1 was visualized by green fluorescent protein (GFP) 24 hours later on fluorescence microscopy. (magnification,
6400). B. Cardiomyocytes were infected by with Ad-GFP, Ad-Nrdp1 or Ad-Dn-Nrdp1 and then treated with 5 mM DOX for 24 hr. Cell viability was
measured by trypan blue exclusion assay. C. Apoptosis was detected by TUNEL assay. A representative field is shown for each condition (top panels).
Quantitative analysis of TUNEL-positive cells from 3 independent experiments (bottom panels, magnification, 6200). D. Cardiomyocytes were
infected and treated with DOX as in A. Western blot analysis of expression of cleaved poly ADP-ribose polymerase (PARP) protein (top panel).
Quantitative analysis is in the bottom panel. *P,0.01 vs. Ad-GFP.
#P,0.05 vs. Ad-GFP+DOX. Results are expressed as means 6 SEM (n=3).
doi:10.1371/journal.pone.0021104.g002
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DOX-induced LV dilatation was increased in Nrdp1 TG mice
(Figure 6B, C). Importantly, DOX markedly reduced HR, FS and
LVEF in both WT and TG mice (P,0.01), with a greater decrease
in TG than WT mice (P,0.01) (Figure 6D,E,F). Thus, overex-
pression of Nrdp1 in the mouse heart exacerbates the DOX-
induced cardiac dysfunction.
Survival analysis
Ten days after saline treatment, WT and Nrdp1 TG mice did
not differ in survival. Ten days after DOX treatment, the survival
was significantly lower in TG than WT mice (17% vs. 53%,
P,0.01). The survival was markedly lower in DOX-treated than
untreated WT controls (53% vs 100%, P,0.01) (Figure 7).
Therefore, overexpression of Nrdp1 in the heart reduced prolonged
survival.
Effect of Nrdp1 on activation of Akt, ERK1/2 and STAT3
signaling pathways after DOX treatment in rat neonatal
cardiomyocytes
Three classes of signaling pathways, Akt, ERK1/2 and
STAT3, are involved in DOX-induced cardiotoxicity [13,17,18,
19,20], so we detected the activation of Akt, ERK/12 and
STAT3 in neonatal rat cardiomyocytes by western blot analysis.
The levels of phosphorylated Akt, ERK1/2 and STAT3 were
similar among groups with saline treatment (Figure 8). At 24 hr
after DOX treatment, the levels of phosphorylated Akt, ERK1/
2 and STAT3 were decreased in Ad-GFP-infected cardiomyo-
cytes, with the levels further lowered in Nrdp1-infected cells than
in the GFP control. However, the levels were markedly
alleviated in Ad-Dn-Nrdp1-infected cells as compared with Ad-
Nrdp1-infected cells (Figure 8). Levels of total Akt, ERK1/2 and
STAT3 did not differ among groups (Figure 8). Thus, Nrdp1
Figure 3. Cardiac-specific overexpression of Nrdp1 aggravates DOX-induced cardiac injury and cardiomyocyte apoptosis. A. H&E
staining of heart sections on day 5 after saline or DOX treatment (n=4 per group). Arrows indicate representative vacuolization. Magnification6200.
B. Representative electron microphotographs of cardiac sections from wild type (WT) (left panel) and Nrdp1 transgenic (TG) mice (right panel) treated
with saline or 20 mg/kg DOX for 4 days (n=3 per group). Arrows indicate cytoplasmic vacuolization. Scale bars=1 mm. C. Quantitative results of
cardiomyocyte apoptosis detected by TUNEL assay (n=4 per group). D. Western blot analysis of protein level of cleaved PARP and p53 in WT and
Nrdp1 TG mice treated with saline or DOX (n=5 per group). Quantitative analysis is in the bottom panels. *P,0.01 vs WT+saline mice;
# P,0.01 vs
WT+DOX mice.
doi:10.1371/journal.pone.0021104.g003
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ERK1/2, and STAT3-dependent signaling pathways.
Discussion
Nrdp1, as an E3 liagse, has been extensively investigated for
apoptosis and inflammation activity in cancer cells and other cell
types [5,6,7,8,9,10,11]; however, the effect of Nrdp1 on DOX-
induced cardiotoxicity and underlying mechanisms has been less
well studied. We revealed a critical role for Nrdp1 in the
development of cardiac injury after DOX treatment. Overexpres-
sion of Nrdp1 in vivo in mouse hearts and in vitro in cardiomyocytes
enhanced DOX-induced cardiomyocyte apoptosis, autophagy and
oxidative stress, thus resulting in more severe LV contractile
dysfunction and mouse mortality after DOX injury. These
changes were associated with inactivation of Akt, ERK1/2, and
STAT3 signaling pathways. Nrdp1 may be an important
contributor in DOX-induced cardiac dysfunction.
Emerging evidence indicates that DOX induces cardiac injury
via several mechanisms, including free radical generation,
apoptosis and autophagy [15,17,21]. Cardiomyocyte apoptosis is
one of the critical events in DOX-induced heart failure [17,21].
Nrdp1 promotes degradation of BRUCE/apollon, a 530-kDa
membrane-associated inhibitor of apoptosis protein, thereby
promoting apoptosis [9]. A recent study indicated that Nrdp1
functions as a critical regulator of Toll-like receptor responses [10].
However, the role of Nrdp1 in DOX-induced cardiac injury
remains unclear. In vitro studies in neonatal cardiomyocytes
showed increased expression of Nrdp1 markedly enhancing
DOX-induced cardiomyocyte apoptosis and the levels of cleaved
PARP, an indicator of programmed cell death; infection with Dn-
Nrdp1 markedly attenuated this effect (Figure 2). Importantly,
Nrdp1 TG mice after DOX injection exhibited severe myocardial
injury and a significant increase in TUNEL-positive cardiomyo-
cytes and levels of cleaved PARP and p53 expression (Figures 2
and 3), thus leading to severe cardiac dysfunction and increased
mortality in Nrdp1 TG mice (Figures 6 and 7). These results suggest
that extensive apoptosis might be the major contributor to the
decreased survival and cardiac dysfunction observed in Nrdp1 TG
mice after DOX injury.
Autophagy, an intracellular bulk degradation process, is
sensitive to physiological regulation, such as the supply and
deprivation of nutrients. Sixteen proteins participate in the
autophagy pathway in humans [16]. Besides increasing activities
of cellular degradation pathways such as calpain and the ubiquitin
proteasome system [22,23]. DOX induces autophagy in cardio-
myocytes [15]. Importantly, 3-methyadenine, an autophagy
inhibitor, can reduce DOX-induced cardiomyocyte death, which
suggests that autophagy activation may contribute to DOX-
induced cardiotoxicity. Autophagy is often associated with
apoptosis, which can act in partnership to coordinately induce
cell death [16]. In the present study, we showed that DOX greatly
increased the ratio of LC3-II to LC3-I, a marker of autophagy
activation, and accumulation of vacuoles in cardiomyocytes.
Overexpression of Nrdp1 further enhanced these effects (Figure 4),
which indicates that Nrdp1 may mediate cardiac injury after DOX
by inducing autophagy. Further studies are needed to address the
exact molecular functions of Nrdp1 in the activation of autophagy
in the heart.
Oxidative stress can directly induce cell damage, cell apoptosis
and autophagy [15,21]. Several studies have demonstrated that
agents such as statins that scavenge ROS protect against DOX-
induced cardiac apoptosis [3,24]. Furthermore, cardiac-specific
overexpression of antioxidant genes, including manganese super-
oxide dismutase and catalase, protect mice against DOX-induced
cardiac dysfunction [25,26,27]. More recently, increased expres-
sion of Nrdp1 enhanced the production of ROS, whereas this effect
was attenuated by knockdown of Nrdp1 by siRNA in SH-SY5Y
cells [7]. We found that DOX stimulated Nrdp1 expression, so
Nrdp1 can be activated by oxidative stress such as DOX (Figure 1).
Furthermore, after DOX injection, as compared with WT mice,
Nrdp1 TG mice showed a marked increase of MDA levels and
decrease of GPX activity as indexes of oxidative stress (Figure 5).
Thus, Nrdp1 also plays a critical role in the generation of oxidative
stress in the heart. However, the precise mechanisms involved in
the interaction between Nrdp1 and oxidative stress still need further
investigation.
Figure 4. Nrdp1 TG mouse hearts are more susceptible to DOX-
induced autophagy. A. Western blot analysis of ratio of LC3-II to -I
protein level from WT and Nrdp1 TG heart tissue after saline or DOX
treatment. A representative blot is shown for each condition (top
panels). b-actin was used as a loading control. Histograms show relative
intensity of the ratio of LC3-II to -I (n=4 per group) (bottom panel).
*P,0.05 vs WT+saline mice;
# P,0.05 vs WT+DOX mice. B.
Representative electron microphotographs of cardiac sections from
WT (left panel) and Nrdp1 TG mice (right panel) treated with 20 mg/kg
of DOX for 4 days (n=3 per group). Arrows indicate autophagic
vacuoles and electron-dense lysosomes. Scale bars=1 mm.
doi:10.1371/journal.pone.0021104.g004
Nrdp1 Exacerbates DOX-Induced Cardiotoxicity
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activity (B) were measured to estimate extent of lipid peroxidation and antioxidation in heart homogenates from WT and Nrdp1 TG mice (n=5 per
group) treated with saline or DOX. *P,0.05 vs WT+saline mice;
# P,0.05 vs WT+DOX mice.
doi:10.1371/journal.pone.0021104.g005
Figure 6. Overexpression of Nrdp1 reduces cardiac function after administration of DOX. (A) Representative M-mode echocardiograms of
WT and Nrdp1 TG mice treated with saline or DOX. Quantitative group data for echocardiographic measurements: (B) HR; (C) LVEDD; (D) LVESD; (E) FS;
and (F) EF. Data were from 10 mice in each group. *P,0.05 vs WT+saline group,
#P,0.05 vs WT+DOX group. Abbreviations are defined in the text.
doi:10.1371/journal.pone.0021104.g006
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STAT3 have been implicated in mediating DOX cardiotoxicity
[13,17,18,19,20,28]. Previous studies demonstrated that DOX
treatment caused myocardial damage and reduced phosphoryla-
tion of Akt and ERK1/2 [28], whereas activation of Ras/MEK/
ERK and Akt signaling can inhibit DOX-induced apoptosis and
ameliorate DOX-induced congestive heart failure [13,18,20,28].
Furthermore, mice with cardiac-specific deletion of STAT3
showed greater susceptibility to cardiac injury after DOX
treatment [19]. For further insight into the mechanisms of Nrdp1
in DOX-induced cardiotoxicity, we examined activation of these
signaling pathways. Overexpression of Nrdp1 decreased the
phosphorylation of Akt, ERK/12, and STAT3, and the decreased
kinase activity was reversed with Dn-Nrdp1 infection in cardiomy-
ocytes (Figure 8). Thus, Nrdp1 has an important role in regulating
the activation Akt, ERK1/2, and STAT3 signaling pathways in
the heart during DOX injury.
Conclusions
In the present study, we demonstrate that in response to DOX
treatment, Nrdp1 protein is upregulated in mouse hearts and
cardiomyocytes, which results in increased cardiac apoptosis,
autophagy, and generation of oxidative stress and thus cardiac
injury and dysfunction. These effects are associated with
inactivation of Akt, ERK1/2 and STAT3 signaling pathways.
Therapeutic strategies such as pharmacological inhibition to block
Nrdp1 activation may help prevent cardiac apoptosis, autophagy
and oxidative stress and thereby attenuate DOX cardiotoxicity.
Materials and Methods
Antibodies and reagents
The plasmids of mouse wild-type Nrdp1 and dominant-negative
form of Nrdp1 (C34S/H36Q) were a kind gift from Dr. Xiaobo
Qiu (College of Life Sciences, Beijing Normal University, China).
Anti-Nrdp1 (BETHYL Laboratories, Inc), anti-cleaved PARP, anti-
total- and phospho-AKT (Ser473), -ERK1/2 (Thr202/Tyr204), -
STAT3, Tyr705) and horseradish peroxidase-conjugated goat
anti-mouse or anti-rabbit IgG secondary antibody were from Cell
Signaling Technology. Anti-light 1 chain 3 (anti-LC3) was from
MBL International Operation; anti-p53 and anti-b-actin were
from Santa Cruz Biotechnology. Doxorubicin (DOX) and other
reagents were from Sigma-Aldrich.
Cell culture and adenoviral constructs
Neonatal rat cardiomyocytes were isolated from 1-day-old
Sprague-Dawley rats by enzymatic disassociation [29]. Recombi-
nant adenoviruses expressing green fluorescent protein (GFP)
alone (Ad-GFP), Nrdp1 (Ad-Nrdp1) and the dominant-negative
form of Nrdp1 (C34S/H36Q) (Ad-Dn-Nrdp1) driven by the
cytomegalovirus promoter were generated by use of AdEasy
(MP Biomedicals Inc.) [12,29]. Twenty-four hours after plating,
cells were infected with Ad-GFP, Ad-Nrdp1, or Ad-Dn-Nrdp1 for
24 hr and then treated with 0.5 mM DOX for the indicated times.
Cell viability was determined by Trypan blue exclusion assay [30].
Animals and treatments
Nrdp1 transgenic mice (TG) were generated and characterized
as described [12,29]. Male wild-type (WT) and Nrdp1 transgenic
(TG) mice in the same C57BL/6 background were 8 to 10 weeks
old. WT (n=106) and Nrdp1 TG (n=94) mice were randomly
Figure 7. Survival rate. Ten-day survival was analyzed in WT and
Nrdp1 TG mice treated with DOX (20 mg/kg). Survival was analyzed by
the Kaplan-Meier approach and the log-rank test (n=15 per group).
*P,0.05 vs WT+saline mice;
# P,0.05 vs WT+DOX mice.
doi:10.1371/journal.pone.0021104.g007
Figure 8. Effect of Nrdp1 on the phosphorylation of Akt, ERK1/2
and STAT3 in rat neonatal cardiomyocytes. Rat neonatal
cardiomyocytes were infected by with Ad-GFP, Ad-Nrdp1 or Ad-Dn-
Nrdp1 and then treated with 0.5 mM DOX for 24 hr. Western blot
analysis of protein levels of phosphorylated and total Akt, ERK1/2 and
STAT3 (n=4 per group, top panels). b-actin was used as a loading
control. A representative blot is shown for each condition. Quantitative
analysis is in the bottom panel. *P,0.05 vs. Ad-GFP+saline;
#P,0.05 vs.
Ad-GFP+DOX.
doi:10.1371/journal.pone.0021104.g008
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(20 mg/kg) was administered by intraperitoneal (ip) injection as
described [13]. Control mice received injections of saline at a
comparable volume. All procedures were approved by and
performed in accordance with the Animal Care and Use
Committee of Capital Medical University (20090916). The
investigation conformed to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH, 1996).
Echocardiography
Male WT and Nrdp1 TG mice (n=10 per group) were lightly
anesthetized with tribromoethanol (0.25 mg/g ip). Four days after
DOX or vehicle (saline) injection, mice underwent high-resolution
micro-ultrasonography (Vevo 770, VisualSonics Inc., Toronto,
Canada) [29]. The left ventricular end diastolic diameter
(LVEDD),left ventricular end systolic diameter (LVESD), LV
fractional shortening (LVFS), LV ejection fraction (LVEF) and
heart rate (HR) were measured. All variables were measured in the
parasternal long-axis view over at least 5 consecutive cardiac cycles
and averaged from at least 2 measurements. LVFS was calculated
as [(LVEDD2LVESD)/LVEDD]6100.
Morphological examination and TUNEL assay
Hearts were fixed with 10% formalin and embedded in paraffin.
Heart sections (thickness, 5 mm) were stained with hematoxylin and
eosin (H&E). Sections were also examined for apoptotic cardiomy-
ocytes by TdT-mediated dUTP Nick-End Labeling (TUNEL) assay
(TUNEL fluorescence FITC kit, Roche, USA) [31]. DAPI reagent
wasused tocounterstainnuclei.Thepercentage ofTUNEL-positive
myocytes was determined by counting 10 random fields per section
under a microscope (Leica, Germany).
Electron microscopy
Ultrastructural injury in cardiac tissues of mice (n=3 per group)
treated with vehicle (saline) or DOX for 5 days was evaluated by
electron microscopy. Heart tissue was cut into 1 mm
3 pieces and
immersion-fixed overnight in phosphate buffered 2.5% glutaral-
dehyde (pH 7.4), postfixed for 1 hr with 1% osmium tetroxide,
dehydrated through a graded ethanol series, and embedded in
Epon medium. Ultrathin sections (60–70 nm) were stained with
uranyl acetate and lead citrate and observed under a JEOL 100-
CX transmission electron microscope.
Measurement of lipid peroxidation and antioxidant
enzymes in the left ventricle
LV malondialdehyde (MDA) level as an indicator of lipid
peroxidation was measured by use of the commercially available
colorimetric assay kit (Nanjing Jiancheng Bioengineering Inst.,
China). Antioxidant enzyme was measured by assay of glutathione
peroxidase (GPX) (Calbiochem).
Western blot analysis
Western blot analysis was as described [29]. Protein samples
from cardiomyocytes or heart tissues were separated by SDS-
PAGE, transferred onto immobilon-P membrane (Millipore), then
incubated with primary and secondary antibodies. Relative
protein levels were normalized to that of b-actin.
Statistical analysis
Data are presented as mean 6 SEM. Comparison between
groups involved Student’s t test or one-way ANOVA. Survival
after DOX injection in mice was analyzed by the Kaplan-Meier
method and compared by a log-lank test. A P,0.05 was
considered statistically significant.
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